Related Experiment Video
Updated: Apr 27, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Impact of antiretroviral medications on fasting lipid parameters
Giovanni Guaraldi, Antonella Santoro, Chiara Stentarelli
1Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Italy; Infectious Disease Clinic, Azienda USL 4 Prato, Italy.
Abstract:
It is widely accepted that metabolic disease in human immunodeficiency virus (HIV) develops at the intersection of traditional risk factors and HIV-specific contributors, but in observational studies it is difficult to dissect the contribution of the two. This review describes the metabolic impact of antiretroviral medications recommended in the first-line treatment in HIV-infected naive patients. At a clinical level, coronary heart disease screening and management will continue to be of paramount importance in the long-term management of HIV-positive patients on antiretroviral therapy.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Retrovirus Life Cycles
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Inhibitors of Viral Protein Synthesis
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

